Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
Armgo Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics for debilitating cardiac, skeletal muscular, and neurological disorders. The company specializes in calcium release channel stabilizers known as Rycals, which target the ryanodine receptor/calcium release channel located on the sarcoplasmic/endoplasmic reticulum of cells. These therapeutics are designed to address various conditions, including chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Founded in 2004, Armgo Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.
Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Theseus Pharmaceuticals
Series B in 2021
Theseus Pharmaceuticals is a Technology based company.
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.
Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.
StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.
EyeYon Medical Ltd. develops medical devices for the treatment of corneal edema. The company’s products include Hyper-CL, a hyperosmotic contact lens that extracts fluids from the corneal edema by osmosis; and DSPEK, an artificial endothelial layer for replacing an injured endothelial layer that may cause corneal edema. Its hyper osmotic contact lens is designed to improve vision and relieve pain in various clinical situations. EyeYon Medical Ltd. is based in Jerusalem, Israel.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.
The company was incorporated in 2015 and is based in Newton, Massachusetts.
Stargazer Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2018. The company specializes in developing and manufacturing therapies for rare eye diseases, with a particular focus on Stargardt’s disease, a form of juvenile retinal degeneration. Currently operating in stealth mode, Stargazer Pharmaceuticals aims to provide novel treatment options for conditions that lack existing therapies, thus enabling healthcare professionals to better address the needs of patients with these rare diseases.
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
Neogene Therapeutics, Inc. develops T cell therapies to treat cancer. The company was incorporated in 2018 and is headquartered in New York, New York.
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it.
Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
ProQR Therapeutics N.V. is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics aimed at treating genetic disorders. The company is advancing several key product candidates, including sepofarsen, currently in a phase II/III trial for Leber’s congenital amaurosis type 10, and QR-421a, which is in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, while QR-504a is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR Therapeutics has established collaboration agreements with prominent institutions such as General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is headquartered in Leiden, the Netherlands.
Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation. Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON. Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.
Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.
Eyevensys S.A.S. develops non-viral gene therapy treatments for ophthalmology. The company’s develops Electro-Transfection (ET) of plasmids to the ciliary muscle therapy to deliver calibrated and sustained therapeutic proteins preferentially in the vitreous for several months. It develops an Electro-Transfection Injection System (ETIS) which is a drug device solution consisting of a device and a pulse generator. The company focuses on Uveitis, age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME). Eyevensys S.A.S. was incorporated in 2008 and is based in Paris, France.
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.
Raziel Health, founded in 2012 and based in Rehovot, Israel, focuses on transforming healthcare delivery by providing accessible and cost-effective solutions for patients in their homes. The company integrates user-friendly technologies that enhance patient experiences and facilitate timely clinical interventions tailored to individual needs. By leveraging data analytics, Raziel Health supports wellness and disease management, aiming to improve health outcomes while making healthcare more affordable. In addition to its healthcare services, Raziel is developing RZL-012, a novel synthetic small molecule designed for obesity treatment, which works by inducing fat cell death at the injection site to reduce fat tissue.
Adicet Bio is a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
ABAC Therapeutics S.A. develops precision antimicrobial agents for precision treatment of MDR Gram-negative infections. It offers PasNas, a drug discovery platform unveiling pathogen-specific antibacterial properties of molecules while promoting the compounds active against MDR strains with new mechanism of action and with maximized chances of success in clinical development. The company was incorporated in 2014 and is based in Barcelona, Spain. As of November 20, 2019, ABAC Therapeutics S.A. operates as a subsidiary of Tibidabo Ventures.
Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.
ArQule, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for cancer and rare diseases. Based in Burlington, Massachusetts, the company utilizes its ArQule Kinase Inhibitor Platform to create innovative small molecule drugs. ArQule's pipeline includes several promising candidates, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase currently in Phase I trials for B-cell malignancies, and miransertib (ARQ 092), which targets the AKT pathway in advanced endometrial cancer patients. Additionally, ARQ 75 is under Phase I development for solid tumors with specific genetic mutations, while Derazantinib (ARQ 087) is in a registrational trial for intrahepatic cholangiocarcinoma. The company has established licensing agreements with Basilea Pharmaceutica and Roivant Sciences for its products. Founded in 1993, ArQule has positioned itself as a key player in the oncology space, aiming to improve patient outcomes through its specialized therapeutics. As of early 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.
Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.
VBI Vaccines Inc. is a biopharmaceutical company focused on developing vaccines for infectious diseases and immuno-oncology, with operations in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine suitable for various age groups, and is advancing VBI-2601, an immunotherapeutic candidate aimed at achieving a functional cure for chronic hepatitis B. Utilizing its enveloped virus-like particle (eVLP) platform technology, VBI develops vaccines that closely mimic target viruses to elicit strong immune responses. Key candidates in its eVLP program include VBI-1901, a glioblastoma vaccine in Phase I/IIa clinical trials, and VBI-1501, a cytomegalovirus vaccine that has completed Phase I trials. VBI Vaccines also engages in collaboration and licensing agreements with various pharmaceutical and biotechnology entities, including partnerships for the commercialization of its hepatitis B vaccine and the development of a pan-coronavirus vaccine candidate. Headquartered in Cambridge, Massachusetts, the company also has research facilities in Ottawa, Canada.
CathWorks Ltd. is a medical technology company based in Kfar-Saba, Israel, with an additional office in the United States. Founded in 2013, CathWorks specializes in developing advanced medical devices for the interventional cardiology market. The company's innovative technology leverages computational science and automatic multi-layered algorithms to enhance the utility of coronary angiography data, transforming visual assessments into objective decision-making tools for physicians. Its flagship product, CathWorks FFRangio, is a non-invasive device that provides objective multi-vessel physiological measurements, aimed at optimizing and confirming intra-procedural decisions for percutaneous coronary interventions (PCI). CathWorks is privately held and benefits from strong partnerships and support from leading venture capital firms in the medical devices sector.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Tisbury Pharmaceuticals, Inc. discovers, develops, and commercializes therapy to treat primary open angle glaucoma. The company's clinical candidate, R-801, accelerates flow via the trabecular meshwork via redox catalysis and K+-ATP (channel activation). The company was incorporated in 2017 and is based in Beverly, Massachusetts.
TargEDys SAS develops mechanisms involving hormone mimetic proteins linked to microbiota for the treatment of eating disorders such as hyperphagia or anorexia. TargEDys SAS was incorporated in 2011 and is based in Rouen, France.
EyeYon Medical Ltd. develops medical devices for the treatment of corneal edema. The company’s products include Hyper-CL, a hyperosmotic contact lens that extracts fluids from the corneal edema by osmosis; and DSPEK, an artificial endothelial layer for replacing an injured endothelial layer that may cause corneal edema. Its hyper osmotic contact lens is designed to improve vision and relieve pain in various clinical situations. EyeYon Medical Ltd. is based in Jerusalem, Israel.
ARTSaVIT is a biopharmaceuticals company developing a cancer drug.
Eyevensys S.A.S. develops non-viral gene therapy treatments for ophthalmology. The company’s develops Electro-Transfection (ET) of plasmids to the ciliary muscle therapy to deliver calibrated and sustained therapeutic proteins preferentially in the vitreous for several months. It develops an Electro-Transfection Injection System (ETIS) which is a drug device solution consisting of a device and a pulse generator. The company focuses on Uveitis, age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME). Eyevensys S.A.S. was incorporated in 2008 and is based in Paris, France.
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience and networks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience.
TargEDys SAS develops mechanisms involving hormone mimetic proteins linked to microbiota for the treatment of eating disorders such as hyperphagia or anorexia. TargEDys SAS was incorporated in 2011 and is based in Rouen, France.
Sweetch Health Ltd. provides a platform that predicts personal diabetes risk and drives long-term behavioral change to prevent diabetes. The artificial intelligence (AI) technology offers personalized recommendations that can be realistically achieved and are continuously adapted based on the user's past behavior by automatically processing smartphone-originated data streams, including geo-location, schedule, physical activity patterns, driving and walking routes, weather, and surroundings, which are translated into insights about the individual's lifestyle habits. Sweetch Health Ltd. company was founded in 2013 and is based in Jerusalem, Israel.
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.
OCON Healthcare, also known as OCON Medical Ltd., focuses on the development, manufacturing, and commercialization of innovative women's health products utilizing its proprietary IUB (Intra Uterine Ball) platform. The company's flagship product, the IUB Ballerine, is a hormone-free, copper-based intrauterine contraceptive designed for up to five years of use. Additionally, OCON is advancing its SEAD product, currently in Phase II clinical studies, which aims to provide a disposable, point-of-care therapy for abnormal uterine bleeding. The company's offerings also include intrauterine devices designed for various indications, such as abnormal uterine bleeding and infertility. OCON Healthcare serves customers primarily in Europe, South Africa, and Israel. Founded in 2011, the company is headquartered in Modi'in-Maccabim-Re'ut, Israel, with an additional office in Zürich, Switzerland.
Adicet Bio is a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com
EyeYon Medical Ltd. develops medical devices for the treatment of corneal edema. The company’s products include Hyper-CL, a hyperosmotic contact lens that extracts fluids from the corneal edema by osmosis; and DSPEK, an artificial endothelial layer for replacing an injured endothelial layer that may cause corneal edema. Its hyper osmotic contact lens is designed to improve vision and relieve pain in various clinical situations. EyeYon Medical Ltd. is based in Jerusalem, Israel.
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.
Check-Cap is a young and dynamic medical device company with breakthrough solution for Colorectal Cancer Screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
HeadSense Medical is an early-stage company based in Netanya, Israel, with operations in the U.S. It specializes in developing non-invasive brain diagnostic devices, focusing on monitoring intracranial pressure (ICP). The company's flagship product is a validated ICP monitor that has received CE Mark approval, making it suitable for use in neurosurgery, neurology, emergency medicine, and critical care settings. In addition to its initial offering, HeadSense is expanding its product line to include applications for diagnosing cerebral vasospasm, assessing concussions, and quantifying the severity of traumatic brain injuries. Founded in 2011, HeadSense Medical aims to enhance brain health diagnostics through innovative, non-invasive technology.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. It offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. The company is also developing ReWalk Restore, a soft suit exoskeleton for rehabilitation of individuals suffering from a stroke. It markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company’s lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.
Private Equity Round in 2011
MacroCure is a biotechnology company focused on the development and commercialization of advanced cell therapy products. The company's first focus of interest is in the arena of wound care. The technology employs activated white blood cells obtained from young adults healthy donor blood. The activated cells provide the natural environment for wound healing, and ensure that necessary cell activities and factor secretions are maintained as required for wound healing. This novel concept is the first of its kind in the field of wound therapy.
Stimatix GI is an early stage startup company founded in June 2009. The Company operates under the auspices of the Misgav Venture Accelerator, and is jointly funded by the Office of the Chief Scientist and the Misgav Venture Accelerator. Stimatix GI has developed the Artificial Ostomy Sphincter (AOS) product line with its AOS-1000™ and AOS-C2000™ products, unique colostomy devices that provide voluntary bowel evacuation. Aesthetically designed and easy to use, the AOS products seal the stoma and eliminate the problems inherent in wearing traditional adhesive bags. These proprietary low- profile colostomy appliances allow people with stoma to decide, at their convenience, when and where to evacuate. With the AOS products, evacuation routine is easier, quicker, and cleaner than ever. And, as the stoma is hermetically sealed, skin irritation and folliculitis are eliminated.
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company specializes in developing innovative treatments for neurodegenerative disorders. Its primary product candidate, Ladostigil, is designed for mild cognitive impairment and operates through various neuroprotective mechanisms, including the reduction of oxidative stress and inflammatory responses. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease, underscoring its commitment to advancing research in this critical area of healthcare.
Aposense Ltd. is a biopharmaceutical company focused on developing innovative drugs by leveraging the structural and electrical properties of biological membranes. The company specializes in creating molecular nano-motors, which are small chemical entities that harness energy from intra-membrane electric fields. Aposense's Apo-Si platform technology facilitates the delivery of genetic drugs, such as siRNA, into cells. The company's pipeline includes ATT-11T, a conjugate of its proprietary molecular nano-motor with SN-38, aimed at treating solid tumors. Additionally, Aposense is involved in clinical-stage molecular imaging and drug development, targeting apoptosis to enhance personalized patient care across various disease categories, including oncology, cardiology, and neurology. Founded in 1996 and headquartered in Petah Tikva, Israel, Aposense is dedicated to translating the science of apoptosis into effective therapies and real-time clinical imaging.
Applied Immune Technologies Ltd. is involved in the development of therapeutic molecules aimed at treating cancer, viral infections, and autoimmune diseases. The company specializes in creating T-Cell Receptor-Like (TCRL) antibodies that target intracellular-derived peptides for various therapeutic and diagnostic purposes. These TCRL antibodies have applications in pathology, as well as in vaccine design, validation, and monitoring. Additionally, they are useful in analyzing antigen presentation in various diseases. Founded in 2006 and based in Haifa, Israel, the company was previously known as BioMimic Pharma and now operates as a subsidiary of Adicet Bio, Inc.
ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
Aposense Ltd. is a biopharmaceutical company focused on developing innovative drugs by leveraging the structural and electrical properties of biological membranes. The company specializes in creating molecular nano-motors, which are small chemical entities that harness energy from intra-membrane electric fields. Aposense's Apo-Si platform technology facilitates the delivery of genetic drugs, such as siRNA, into cells. The company's pipeline includes ATT-11T, a conjugate of its proprietary molecular nano-motor with SN-38, aimed at treating solid tumors. Additionally, Aposense is involved in clinical-stage molecular imaging and drug development, targeting apoptosis to enhance personalized patient care across various disease categories, including oncology, cardiology, and neurology. Founded in 1996 and headquartered in Petah Tikva, Israel, Aposense is dedicated to translating the science of apoptosis into effective therapies and real-time clinical imaging.
CollPlant Biotechnologies Ltd. is a regenerative medicine company based in Rehovot, Israel, specializing in the 3D bioprinting of tissues and organs, as well as developing tissue repair products for orthobiologics. The company utilizes a proprietary plant-based genetic engineering technology to produce recombinant type I human collagen, known as rhCollagen. Its product offerings include BioInks designed for 3D printing applications, dermal fillers for wrinkle treatment, and advanced solutions like VergenixSTR, a matrix for soft tissue repair targeting tendinopathy, and VergenixFG, which aids in the healing of acute and chronic wounds, including diabetic ulcers and burns. Founded in 2004, CollPlant aims to advance the fields of regenerative and aesthetic medicine through innovative solutions.
CollPlant Biotechnologies Ltd. is a regenerative medicine company based in Rehovot, Israel, specializing in the 3D bioprinting of tissues and organs, as well as developing tissue repair products for orthobiologics. The company utilizes a proprietary plant-based genetic engineering technology to produce recombinant type I human collagen, known as rhCollagen. Its product offerings include BioInks designed for 3D printing applications, dermal fillers for wrinkle treatment, and advanced solutions like VergenixSTR, a matrix for soft tissue repair targeting tendinopathy, and VergenixFG, which aids in the healing of acute and chronic wounds, including diabetic ulcers and burns. Founded in 2004, CollPlant aims to advance the fields of regenerative and aesthetic medicine through innovative solutions.
CollPlant Biotechnologies Ltd. is a regenerative medicine company based in Rehovot, Israel, specializing in the 3D bioprinting of tissues and organs, as well as developing tissue repair products for orthobiologics. The company utilizes a proprietary plant-based genetic engineering technology to produce recombinant type I human collagen, known as rhCollagen. Its product offerings include BioInks designed for 3D printing applications, dermal fillers for wrinkle treatment, and advanced solutions like VergenixSTR, a matrix for soft tissue repair targeting tendinopathy, and VergenixFG, which aids in the healing of acute and chronic wounds, including diabetic ulcers and burns. Founded in 2004, CollPlant aims to advance the fields of regenerative and aesthetic medicine through innovative solutions.
CollPlant Biotechnologies Ltd. is a regenerative medicine company based in Rehovot, Israel, specializing in the 3D bioprinting of tissues and organs, as well as developing tissue repair products for orthobiologics. The company utilizes a proprietary plant-based genetic engineering technology to produce recombinant type I human collagen, known as rhCollagen. Its product offerings include BioInks designed for 3D printing applications, dermal fillers for wrinkle treatment, and advanced solutions like VergenixSTR, a matrix for soft tissue repair targeting tendinopathy, and VergenixFG, which aids in the healing of acute and chronic wounds, including diabetic ulcers and burns. Founded in 2004, CollPlant aims to advance the fields of regenerative and aesthetic medicine through innovative solutions.
CritiSense, Ltd. develops device for monitoring patients metabolic state in real time and as an endpoint of resuscitation. It develops device for monitoring oxygen levels at the tissue level for patients undergoing surgery or in intensive care units. Its CritiView, a monitoring system providing real-time continuous information via four physiological parameters, sensed at the tissue level, and reflecting the patient’s systemic metabolic state and It is used by surgeons, anesthesiologist, and caregivers in ICU to identify tissue and body vitality imbalances. The company was founded in 2004 and is based in Giv'at Shmu'el, Israel.
CritiSense, Ltd. develops device for monitoring patients metabolic state in real time and as an endpoint of resuscitation. It develops device for monitoring oxygen levels at the tissue level for patients undergoing surgery or in intensive care units. Its CritiView, a monitoring system providing real-time continuous information via four physiological parameters, sensed at the tissue level, and reflecting the patient’s systemic metabolic state and It is used by surgeons, anesthesiologist, and caregivers in ICU to identify tissue and body vitality imbalances. The company was founded in 2004 and is based in Giv'at Shmu'el, Israel.